The incidence of malignant melanoma is growing rapidly worldwide and there is still no effective therapy for metastatic disease. Melanoma is the second most common cancer among young adults in the UK, where incidence rates have more than quadrupled since the 1970s. Increased expression of a number of DNA repair genes has been reported in melanoma and this likely contributes to its extreme resistance to conventional DNA-damaging chemotherapeutics. One such chemotherapeutic that is effective against a range of other cancers, but not melanoma, is cisplatin. The DNA repair proteins ERCC1 and XPF are needed to remove cisplatin-induced DNA damage and we have investigated the response of these proteins to cisplatin in melanoma. The expression of both genes is induced by cisplatin. Use of a MEK inhibitor showed that ERCC1, but not XPF induction was regulated by the mitogen-activated protein kinase (MAPK) pathway, with reduction in expression of DUSP6, the phosphatase that inactivates the extracellular signal-regulated kinase (ERK), being particularly important. DUSP6 overexpression prevented cisplatin induction of both ERCC1 and XPF, resulting in increased sensitivity to cisplatin. A novel ERCC1 mRNA was found that initiated upstream of the normal transcription initiation site, and was strongly regulated by both cisplatin and the MAPK pathway and its role in cisplatin resistance merits further study. The cisplatin induction of ERCC1 and XPF provides important insights into the resistance of melanoma to DNA-damaging chemotherapeutics, which is one of the major obstacles to melanoma treatment.
Introduction
The incidence of malignant melanoma is increasing globally faster than for any other form of cancer. Worldwide, around 197 000 people were diagnosed with malignant melanoma in 2008. In the UK, it is the second commonest cancer among young adults (aged 15-34; Cancer Research UK, 2011) . Early stage primary melanomas are often cured by surgery, but up to 20% of patients may go on to develop metastatic disease.
Conventional chemotherapy employing DNA-damaging agents has a proven record of success against many different cancers, but has proven ineffective against metastatic melanoma. A meta-analysis concluded that the standard treatment for metastatic melanoma, the alkylating agent dacarbazine, generally produces poor outcomes (Tsao et al., 2004) , while combinations of chemotherapeutics, such as the Dartmouth regimen, have shown only marginally higher response rates (Chapman et al., 1999) . Such poor responses highlight the unmet need for effective therapy for melanoma.
More targeted therapies have been directed against key pathways in melanomagenesis, such as the mitogenactivated protein kinase (MAPK) pathway. Currently, an inhibitor (PLX4032, also called vemurafenib) of the mutant form of BRAF, found in around 60% of melanomas, has shown very impressive results in clinical trials (Chapman et al., 2011) . However, resistance has already been reported (Johannessen et al., 2010; Nazarian et al., 2010) and, although the agent has shown impressive short-term results, the long-term survival benefit remains to be established. Cancer cells are adept at bypassing blocks in signalling pathways to permit continued proliferation. It will be considerably harder for a melanoma cell to divide if its DNA is heavily damaged and the enzyme activity essential to repair the damage is inhibited.
Cisplatin (CDDP), one of the most widely used chemotherapeutic agents, is particularly active against germ-cell tumours, prolongs survival in ovarian and nonsmall-cell lung cancers, and is important in the treatment of oesophageal, cervical, gastric and prostate cancers (Lebwohl and Canetta, 1998) . The cellular toxicity of cisplatin results primarily from its ability to form intrastrand or interstrand crosslinks. Cells can become resistant through enhanced ability to remove DNA adducts (Martin et al., 2008) . Elevated expression of DNA repair genes has been reported in primary melanomas that subsequently went on to metastasize when compared with non-recurrent primary tumours (Kauffmann et al., 2008) . This increased expression could contribute to the extreme resistance shown by melanoma to conventional DNA-damaging chemotherapeutics.
Nucleotide excision repair (NER) levels are involved in determining resistance or sensitivity to cisplatin (Rabik and Dolan, 2007) . NER removes cisplatininduced intrastrand crosslinks. The ERCC1 protein in combination with XPF forms an endonuclease essential for NER (Petit and Sancar, 1999) , but unlike other NER proteins, ERCC1 and XPF are also involved in repair of cisplatin-induced interstrand crosslinks (Kuraoka et al., 2000) . High ERCC1 expression has been associated in some studies with an inferior outcome following platinum-based chemotherapy in a number of solid tumours, including ovarian and non-small-cell lung cancer (for review, see Kirschner and Melton, 2010) . Cisplatin has been found to enhance ERCC1 expression in a number of cancers, but such induction has not previously been reported for melanoma (for review, see Kirschner and Melton, 2010) .
The MAPK signalling pathway is constitutively activated in malignant melanoma (Oliveria et al., 2006) to regulate cell survival, proliferation and invasion (Hoshino et al., 1999) . Treatment of melanoma cell lines with cisplatin did not cause the anticipated decrease in extracellular signal-regulated kinase (ERK) phosphorylation, but instead resulted in increased phosphorylation (Mirmohammadsadegh et al., 2007) . The MAPK pathway also has an important role in the regulation of ERCC1 expression by epidermal growth factor in human hepatoma cells (Andrieux et al., 2007) . We wished to investigate the hypothesis that cisplatin activates ERK causing increased ERCC1 expression to protect melanoma cells from DNA damage.
DUSP6, a member of the subfamily of protein tyrosine phosphatases known as dual-specificity phosphatases, dephosphorylates ERK (Bermudez et al., 2010) . A recent study suggested cisplatin causes degradation of DUSP6, leading to aberrant ERK activation that contributes to chemoresistance of human ovarian cancer cells (Chan et al., 2008) . In addition, cisplatin-mediated transcriptional inhibition of DUSP6 contributes to the delayed and long-lasting accumulation of ERK phosphorylation that is driven by cisplatin in neurons (Gozdz et al., 2008) . There is a lack of similar reports in other human cancers. We further postulated that decreased DUSP6 levels contribute to ERK activation during cisplatin treatment of melanoma cells.
Results
Increased levels of ERK phosphorylation and induction of ERCC1 and XPF after cisplatin treatment in human melanoma cells To investigate the molecular mechanisms of cisplatin resistance in human melanoma, A375 cells were treated with cisplatin (6 mM) and protein lysates obtained at various time points were western blotted to determine the levels of p-ERK1, p-ERK2 and ERCC1. Total ERK and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels were also determined to correct for variations in protein loading (Figure 1a) . Cisplatin treatment caused a time-dependent increase in the ratio of p-ERK1/2:total ERK1/2. ERK activation increased after 24-h treatment with cisplatin and attained a peak 3.5-fold increase at 48 h (Po0.001; Figure 1b ). Cisplatin induced a similar time-dependent ERCC1 increase. The ERCC1/GAPDH protein ratio was increased at 24 h and peaked at fivefold the control level at 48 h (Po0.001; Figure 1c ). Any increase in ERCC1 protein levels could not boost repair of cisplatin-induced DNA damage without a compensatory increase in its obligate partner XPF. We observed a similar time-dependent increase in XPF levels, with a fivefold increase in the XPF/GAPDH protein ratio at the 36-and 72-h time points (Figures 1d and e) . Next, the role of the MAPK pathway in cisplatin induction of ERCC1 and XPF was investigated in more detail.
The MAPK pathway regulates ERCC1 protein levels following cisplatin treatment in human melanoma cells A specific inhibitor of MEK1/2 (PD0325901; Ciuffreda et al., 2009 ) was used to determine the requirement for ERK activation in the cisplatin induction of ERCC1. Human melanoma A375 cells were treated with cisplatin (6 mM), PD0325901 (1 mM), or both cisplatin and PD0325901 for 24, 48 and 72 h and the protein lysates obtained were western blotted to determine the levels of p-ERK and ERCC1 ( Figure 2a ). As before, p-ERK levels in cisplatin-treated cells increased threefold at 48 h (Po0.001). No p-ERK bands were detected in cells treated with PD0325901, or in cells treated with both cisplatin and PD0325901, indicating that PD0325901 effectively inhibited ERK activation following cisplatin treatment (Figure 2b ). Cisplatin treatment again resulted in increased ERCC1 protein levels, with a peak 4.5-fold increase in the ERCC1/GAPDH ratio after 48 h (Po0.01, Figure 2c ). The MEK inhibitor efficiently prevented this cisplatin-induced increase in ERCC1 protein (Po0.01). PD0325901 alone did not affect the basal level of ERCC1 protein at 48 and 72 h. We conclude that ERK activation has an important role in the regulation of ERCC1 protein levels after cisplatin treatment in melanoma cells.
Cisplatin induction and MAPK pathway regulation of ERCC1 mRNA levels in human melanoma cells To determine if ERCC1 and XPF mRNA levels were also increased following cisplatin treatment and whether the MAPK pathway regulated their induction, A375 cells were treated with cisplatin (6 mM), PD0325901 (1 mM), or both cisplatin and PD0325901 for 24, 48 and 72 h and RNA was extracted for real-time reverse transcriptase (RT)-PCR analysis of ERCC1 and XPF mRNA levels using a validated comparative C T method (see Materials and methods section). b-Actin was used as the internal control in order to normalize the expression of ERCC1 and XPF. As with the protein experiments, cisplatin treatment resulted in increased ERCC1 mRNA levels, the peak was at 3.5-fold the control level at 48 h (Po0.001, Figure 3a) . The MEK inhibitor effectively prevented this cisplatin-induced increase in ERCC1 mRNA (Po0.001). PD032501 on its own had no effect on basal levels of ERCC1 mRNA. We conclude that ERK activation also has an important role in the regulation of ERCC1 mRNA levels after cisplatin treatment in melanoma cells. Cisplatin treatment also resulted in increased XPF mRNA levels; the peak was 2.5-fold the control level at 24 h (Po0.01), earlier than for ERCC1 mRNA. Unlike the induction of ERCC1 mRNA, XPF mRNA induction by cisplatin was not blocked by the MEK inhibitor at any of the time points, and PD032501 alone appeared to cause a significant increase in XPF mRNA levels at 24 h (Po0.01).
DUSP6 phosphatase levels decrease following cisplatin treatment of human melanoma cells We have shown above that p-ERK levels increase after cisplatin treatment. ERK1/2 can be inactivated by dephosphorylation and it has been suggested that accumulation of p-ERK can result from reduced levels of the DUSP6 phosphatase (Bermudez et al., 2010) . To investigate whether DUSP6 was involved in cisplatin effects in human melanoma, A375 cells were treated with cisplatin (6 mM) for 24, 48 and 72 h and the protein lysates obtained were western blotted to determine the levels of p-ERK and DUSP6 ( Figure 4a ). DUSP6 levels decreased as p-ERK levels increased. After 48 h of cisplatin treatment, the DUSP6/GAPDH ratio was threefold lower than in untreated cells (Po0.001, Figure 4c ), coinciding with a peak threefold increase in the p-ERK:total ERK ratio (Po0.001, Figure 4b ). We then went on to investigate further the role of DUSP6 in cisplatin induction of ERCC1 and XPF mRNA.
DUSP6 is a negative regulator of ERK in human melanoma cells A375 cells were transfected with a DUSP6 expression plasmid that also contained a neomycin resistance selective marker. Cells stably expressing DUSP6 were selected with neomycin and two independent pools of neomycin-resistant transfectant colonies were obtained. Pools containing 4100 individual colonies were used rather than individual colonies to smooth out position effects associated with individual DUSP6 integrations and so obtain a more accurate estimate of DUSP6 expression levels. Protein lysates obtained from nontransfected A375 cells and A375 DUSP6 transfectant pools 3 and 4 were western blotted to determine the levels of DUSP6 and p-ERK ( Figure 5a ). The mean DUSP6/GAPDH protein ratio increased two-to threefold in the transfected cells compared with controls ( Figure 5b ) and this was accompanied by a twofold reduction in the p-ERK/total ERK ratio ( Figure 5c ). We conclude, as expected, that DUSP6 negatively regulates p-ERK levels in human melanoma cells.
DUSP6 overexpression prevents cisplatin induction of ERCC1 and XPF mRNA in human melanoma cells DUSP6 overexpression in the A375 transfectant pools reduced basal levels of ERCC1 mRNA around fivefold (Po0.001, Figure 6a ), but did not significantly affect basal levels of XPF mRNA (Figure 6b ). To investigate whether DUSP6 overexpression could prevent ERCC1 and XPF induction following cisplatin treatment, A375 and the A375 DUSP6 transfectant pools were treated with cisplatin for 48 h. We have previously shown that this was the optimal treatment time for ERK activation and ERCC1 and XPF induction. DUSP6 overexpression in the transfected pools effectively prevented induction of both ERCC1 (Figure 6c ) and XPF mRNA (Figure 6d ). We conclude that DUSP6 negatively regulates ERCC1 and XPF induction by cisplatin in human melanoma cells. ERCC1 and cisplatin resistance in melanoma W Li and DW Melton DUSP6 overexpression reduces cisplatin resistance of human melanoma cells To investigate the effect of the DUSP6 overexpressioninduced block of ERCC1 and XPF induction on cisplatin resistance a colony-forming survival assay was first carried out on non-transfected A375 cells and A375 DUSP6 transfectant pools 3 and 4. The relative plating efficiencies obtained indicated that both DUSP6 transfectant pools were more sensitive to cisplatin than their A375 parent (Supplementary Figure 1) . The heterogeneous range of colony sizes obtained, particularly after cisplatin treatment, made quantification and determination of reliable IC 50 values difficult. So sulforhodamine B assays were used instead to determine the cisplatin sensitivities more rigorously. A growth rate experiment was first carried out in control medium to show that A375 DUSP6 transfectant pools had the same growth rate as non-transfected A375 cells (Supplementary Figure 2) . Thus, any difference in the response to cisplatin between the cell lines could not be explained simply on the basis of different growth rates of the untreated cell lines. Cisplatin survival curves for A375 and DUSP6 transfectant pool 3 ( Figure 7a ) and A375 and DUSP6 transfectant pool 4 (Figure 7b ) are shown. In the first experiment, the IC 50 for A375 was 0.59 ± 0.05mM, while the IC 50 for A375 transfectant pool 3 was twofold lower, 0.30 ± 0.02mM (Po0.001).
In a separate experiment, the IC 50 for A375 was 0.51±0.03mM, while the IC 50 for A375 transfectant pool 4 was again significantly lower, 0.31 ± 0.02mM (Po0.001) and we conclude that DUSP6 overexpression renders melanoma cells more sensitive to cisplatin.
An upstream promoter regulated by the MAPK kinase pathway is involved in cisplatin induction of ERCC1 mRNA In mouse skin and cultured mouse keratinocytes, we have previously shown that ERCC1 protein is encoded by a larger Ercc1 transcript, originating from an upstream promoter (Song et al., 2011) . Although no such transcript has previously been clearly demonstrated in human cells, we decided to investigate the possibility that such a transcript might be involved in cisplatin induction of ERCC1 in human melanoma cells. We first deployed a semi-quantitative RT-PCR assay, analogous to that used previously in the mouse (Song et al., 2011) , to detect novel human ERCC1 mRNAs originating upstream of the normal transcription initia- tion site (henceforth referred to as upstream ERCC1 mRNAs) in untreated A375 cells and cells treated for 48 h with cisplatin (6 mM), or both cisplatin and PD0325901 (1 mM) (Figure 8a) . The H-exon1-A forward primer, in combination with H-exon 2-3 reverse primer, detects the exon 1-2 region common to all ERCC1 mRNAs (Figure 8a ; Winter et al., 2005) . The expected 206-bp PCR product was seen at similar levels in all samples, as was a previously described 164-bp product, generated by alternative splicing of a 42-bp region in ERCC1 exon1 (Winter et al., 2005) . The H-exon 2-3 reverse primer was also used in combination with forward primer Hskin3RT, located 139-bp upstream of the normal transcription initiation site (van Duin et al., 1987) , to detect any ERCC1 mRNAs initiating upstream. The expected products from upstream mRNAs (375 bp and 333 bp from the alternative splice) were seen at similar intensities in both untreated and cisplatintreated A375 cells. However, no upstream mRNA signals were seen in cells treated with both cisplatin and the MEK inhibitor. We conclude that ERCC1 mRNAs initiating upstream do indeed occur in human melanoma cells and that the MAPK pathway is involved in their regulation.
To investigate quantitatively the relationship between upstream ERCC1 mRNAs and cisplatin induction a custom TaqMan quantitative RT-PCR assay was used, based on 139 bp of ERCC1 5 0 sequence upstream of the normal initiation site. As with the assay for all ERCC1 mRNAs, b-actin was used as the internal control to normalize expression of upstream ERCC1 mRNAs ERCC1 and cisplatin resistance in melanoma W Li and DW Melton using a validated comparative C T method. Figure 8b shows the 3.5-fold induction of total ERCC1 mRNA levels described previously after 48 h of cisplatin treatment and the action of the MEK inhibitor in blocking this induction, while leaving the basal levels of total ERCC1 mRNA unaffected. A different pattern was observed for upstream ERCC1 mRNAs. Cisplatin treatment caused a larger, fourfold increase in upstream ERCC1 mRNAs compared with untreated cells (Po0.001). The MEK inhibitor not only completely abrogated the cisplatin induction, but also led to a significant reduction in basal levels of upstream ERCC1 mRNAs (Po0.001), as suggested earlier by the semiquantitative RT-PCR assay. We conclude that ERCC1 mRNAs initiating upstream in human melanoma cells are also induced by cisplatin and regulated by the MAPK pathway.
Discussion
The use of platinum drugs in cancer chemotherapy is limited by acquired or intrinsic resistance. Melanoma shows intrinsic resistance to cisplatin. A number of mechanisms of cisplatin resistance have been recognized in cancer cells: increased reflux, or increased inactivation by sulfhydryl molecules, such as glutathione; altered expression of proteins in signal transduction pathways that control apoptosis; increased DNA repair (Shahzad et al., 2009 ). An improved understanding of the mechanisms of resistance is needed to increase the utility of cisplatin for the treatment of cancer. Cisplatin-induced intrastrand crosslinks are repaired by nucleotide excision repair. ERCC1, in combination with XPF, forms an endonuclease essential for NER (Petit and Sancar, 1999) , Unlike other NER proteins, ERCC1 and XPF are also involved in the repair of cisplatin-induced interstrand crosslinks (Kuraoka et al., 2000) , potentially making them of particular importance in cisplatin resistance. We found that cisplatin induced a time-dependent increase in protein and mRNA levels for both ERCC1 and XPF in human melanoma cells. XPF levels are rarely determined along with ERCC1, but an increase in ERCC1 can only boost repair if there is a corresponding increase in its partner-a point that is overlooked in many studies.
Although not previously reported for melanoma, studies have shown higher levels of ERCC1 in other cisplatin-resistant tumours (for review, see Kirschner and Melton, 2010) . ERCC1 overexpression in non-small lung tumours was related to cisplatin resistance and resistance decreased after antisense ERCC1 inhibition (Rosell et al., 2003) . Ovarian cancer lines that developed resistance after exposure to cisplatin in vitro were found to have increased ERCC1 levels (Ferry et al., 2000) . Most testicular cancer patients are cured by cisplatin (Bosl and Motzer, 1997) and most testicular cancer cell lines have low levels of ERCC1 and XPF (Koberle et al., 1997 (Koberle et al., , 1999 Welsh et al., 2004) . Our data suggest that ERCC1 and XPF induction during cisplatin treatment contribute to the resistance of melanoma to chemotherapy.
The MAPK pathway has a major role in regulation of cell growth and differentiation (Johnson and Vaillancourt, 1994) . Many studies have demonstrated MAPK activation in response to cisplatin (for example, Brown et al., 1993; Mirmohammadsadegh et al., 2007) . However, the role of the MAPK pathway in the cisplatin response is complex (Brozovic and Osmak, 2007) . Although some studies showed a role in induction of apoptosis (Wang et al., 2000) , most reports suggest instead that it enhances survival of cisplatin-treated cells (Wang et al., 1998; Persons et al., 1999) . In melanoma, overexpression of activated N-RAS has been reported to protect melanoma cells and enhance cisplatin resistance (Jansen et al., 1997) .
Several studies showed that ERK, one of the kinases in the MAPK pathway, was activated in response to a range of DNA-damaging agents, including cisplatin (Stecca and Gerber, 1998) . Our findings confirmed previous results that cisplatin treatment increased ERK activation in melanoma cell lines and enhanced drug resistance (Mirmohammadsadegh et al., 2007) . Furthermore, we showed that inhibition of MEK prevented the cisplatin-induced increase in ERCC1 protein and mRNA. Previous studies have shown that ERCC1 induction by epidermal growth factor was dependent on regulation of the MAPK pathway by the GATA transcription factor (Andrieux et al., 2007) . Activated H-Ras upregulated ERCC1 through increased transcriptional activity of AP-1 in NIH3T3 and MCF-7 cells (Agar and Young, 2005) . In addition, an ionizing radiation-induced ERCC1 increase in prostate cancer cells also depended on ERK activation (Yacoub et al., 2003) . Moreover, blocking ERK activation with a MEK inhibitor decreased cisplatin-induced ERCC1 protein levels in lung cancer cell lines (Ko et al., 2010) . In a similar way, our data indicate that the MAPK pathway regulates ERCC1 mRNA and protein levels following cisplatin treatment in melanoma cells.
In contrast to the usual rapid and transient activation of the ERK signalling cascade in response to stimuli such as growth factors, ultraviolet damage or cytokines (Xia et al., 1995) , the slower response that we observed suggested that ERK activation might occur indirectly through cisplatin-induced cellular damage. ERK phosphorylation may result from activation of upstream members of the MAPK pathway. In this regard an important role for RAS activation in accumulation of ERCC1 mRNA by insulin has been described (LeeKwon et al., 1998) . However, another cause of ERK activation can be inhibition of ERK phosphatases, such as DUSP6 (Kondoh and Nishida, 2007) . Both mathematical models and experimental data showed that DUSP6 was the principal time regulator of ERK signalling (Ekerot et al., 2008) . Thus, we speculated that the cisplatin-mediated, delayed and long-lasting activation of ERK was, at least in part, because of inhibition of the ERK-specific phosphatase, DUSP6.
We found a time-dependent decrease in DUSP6 protein levels in human melanoma cells following ERCC1 and cisplatin resistance in melanoma W Li and DW Melton cisplatin treatment. In addition, overexpression of DUSP6 reduced both ERK activation and basal mRNA levels of ERCC1, but did not affect basal XPF mRNA levels, suggesting that DUSP6 is involved in ERCC1, but not XPF basal expression. Furthermore, induction of both ERCC1 and XPF mRNA by cisplatin was inhibited by DUSP6 overexpression in melanoma cells, suggesting that cisplatin-mediated DUSP6 inhibition increases ERK phosphorylation leading to ERCC1 and XPF induction. Either the decrease in ERCC1 basal expression, or the decrease in cisplatin induction of ERCC1 and XPF by overexpression of DUSP6, could explain the increased sensitivity to cisplatin we observed in DUSP6 overexpressing melanoma cells. Thus, DUSP6 appears to have an important role in resistance of melanoma to cisplatin. Overexpression of DUSP6 has previously been found to reduce ERK activity and sensitize ovarian cancer cells to cisplatin-induced cell death, while DUSP6 knockdown increased cisplatin resistance (Chan et al., 2008) .
We have previously identified a novel Ercc1 mRNA in mouse skin originating from an alternative upstream promoter (Song et al., 2011) . We have now shown that an equivalent ERCC1 mRNA initiating upstream also exists in human melanoma cells and that it is regulated by the MAPK pathway. These upstream ERCC1 mRNAs show stronger cisplatin induction than normal transcripts, are more effectively inhibited by ERK inactivation and so could make an important contribution to cisplatin resistance.
In conclusion, we have shown that expression of DNA repair genes ERCC1 and XPF is induced by cisplatin in melanoma cells and that this induction is regulated by the MAPK pathway, with the role of DUSP6 phosphatase being particularly important. This induction contributes to increased drug resistance, which is one of the major obstacles to melanoma treatment, suggesting that ERCC1 or XPF inhibitors could be used to enhance the effectiveness of cisplatin treatment. Furthermore, understanding this molecular mechanism may assist the development of new therapeutic interventions for melanoma using existing compounds. Simultaneous treatment with cisplatin and a MEK inhibitor may result in synergistic therapeutic effects at tolerable doses of cisplatin. In addition, a novel ERCC1 mRNA initiating upstream was found that was strongly regulated by cisplatin and the MAPK pathway and its role in cisplatin resistance merits further study.
Materials and methods
Mammalian cell culture A375 human malignant melanoma cells, obtained from the European Collection of Cell Cultures, were maintained in Dulbecco's modified Eagle's medium, supplemented with 10% fetal calf serum, 25 U/ml penicillin and 25 mg/ml streptomycin. Drugs were added to the medium 24 h after plating; PD0325901 (Division of Signal Transduction Therapy, University of Dundee) was added 30 min before cisplatin treatment. Growth rate and sensitivity to cisplatin were determined using the sulforhodamine B colorimetric growth assay (Vichai and Kirtikara, 2006) , with 500 cells plated per well in 96-well plates. Plasmid pcDNA3.1/V5-His-DUSP6/MKP-3 (Furukawa et al., 2003) expresses a His-and V5-tagged version of human DUSP6 from the human cytomegalovirus promoter and also contains a neomycin selectable marker. The plasmid was introduced into A375 cells by calcium phosphate transformation (Graham and Van der Eb, 1973) , with selection for stable transformants in 2.4 mg/ml G418 (Life Technologies Ltd, Paisley, UK). Selection was removed after pools of transfected colonies were isolated.
Western blotting
Protein extracts and western blotting were carried out as described (Selfridge et al., 2010) . p-ERK was detected using rabbit polyclonal antibody 9101 (1:500 dilution), ERK was detected using rabbit polyclonal antibody 9102 (1:1000, both from Cell Signaling Technology, Inc, Danvers, MA, USA). ERCC1:rabbit polyclonal antibody sc-10785 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, 1:1000). XPF:mouse monoclonal antibody Ab-5 (Thermo Scientific, Loughborough, UK, 1:1000). DUSP6:rabbit monoclonal antibody ab76310 (Abcam, Cambridge, UK, 1:1000). Loading control GAPDH:mouse monoclonal antibody MAB374 (Chemicon, Millipore, Billerica, MA, USA, 1:20 000). Horseradish peroxidase-conjugated forms of goat anti-rabbit (P0448, 1:3000) and rabbit anti-mouse (P0260, 1:2000) secondary antibodies were from Dako UK Ltd (Ely, UK). Immunoreactive bands were visualized using enhanced chemiluminescence solution (ECL), or ECL-Plus (Amersham Biosciences, Buckinghamshire, UK). The intensities of bands on the western blots were determined by phosphorimagery.
RNA
Total RNA was extracted using RNA-Bee (AMS Biotechnology [Europe] Ltd, Abingdon, UK) according to the manufacturer's instructions. Reverse transcription of RNA was performed using High Capacity RNA-to-cDNA Master Mix (Applied Biosystems, Carlsbad, CA, USA). RT-PCR to detect human upstream ERCC1 mRNAs was as described for the mouse (Song et al., 2011) , except that the following human primers were used: H-exon1-A forward, 5 0 -CTGGCCGTGC TGGCAGTG-3 0 ; H-exon 2-3 reverse, 5 0 -ATTTGTGATACCC CTCGACGAG-3 0 ; Hskin3RT forward, 5 0 -AAACTTAACAG TTTGGGAGCCAGATCCTC-3 0 . Real-time quantitative PCR reactions were carried out using TaqMan Gene Expression Assays (Applied Biosystems), according to the manufacturer's protocols and analysed on an Applied Biosystems 7900HT Fast Real-Time PCR System. The primer pairs used were: all ERCC1 mRNAs, quantitative-PCR TaqMan ERCC1 primer pair Hs01012158_ml; upstream ERCC1 mRNAs, Custom plus TaqMan primer pair based on 139 bp of sequence upstream of the normal ERCC1 initiation site; XPF mRNA, quantitative-PCR TaqMan ERCC4 primer pair Hs00193342_ml; b-actin mRNA, quantitative-PCR TaqMan b-actin primer pair 4310881E. b-Actin was used as the internal control in order to normalize the expression of ERCC1 and XPF. A standard curve was first run for each gene-specific PCR reaction to determine whether the PCR efficiencies of target and internal control gene were equivalent. If the absolute value of the slope of the plot of log dilution factor vs DC T o0.1, then the comparative C T method can be used to analyse real-time RT-PCR data (Livak and Schmittgen, 2001 ). The relative efficiency plot for all ERCC1 vs b-actin gave a slope of 0.047; for upstream ERCC1 vs b-actin the slope was 0.089; for XPF vs b-actin the slope was 0.055. Thus, all passed the test and so the comparative C T method was used to measure the relative concentrations of ERCC1 and XPF mRNA.
